{"id":"W4409822007","doi":"10.1158/1538-7445.am2025-ct251","title":"Abstract CT251: Phase 3 INTerpath-009 study: Individualized neoantigen therapy V940 (mRNA-4157) plus pembrolizumab for resected stage II-IIIB (N2) NSCLC with incomplete pathological response to neoadjuvant immunochemotherapy","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"","keywords":"Pembrolizumab; Medicine; Oncology; Internal medicine; Stage (stratigraphy); Neoadjuvant therapy; Cancer; Immunotherapy; Biology; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001296071,0.001629375,0.001089316,0.0004001245,0.0005536482,0.001511632,0.001121485,0.001642515,0.005490433],"category_scores_gemma":[0.0006034542,0.0004688449,0.001355527,0.000382939,0.0009119375,0.0007991856,0.0003430522,0.004185908,0.001704153],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001623257,"about_ca_system_score_gemma":0.002226302,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001830254,"about_ca_topic_score_gemma":0.004276094,"domain_scores_codex":[0.9996874,0.0001193005,0.00001690296,0.00006248477,0.00004781166,0.00006605589],"domain_scores_gemma":[0.9995971,0.00003807664,0.00008148962,0.00003595931,0.00003216306,0.0002151426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6243863,0.1063972,0.006642014,0.00228803,0.002367711,0.0005694594,0.0003945418,0.005175023,0.1208332,0.001122529,0.02059628,0.1092278],"study_design_scores_gemma":[0.5078591,0.4585482,0.01010912,0.0001245842,0.0007258296,0.0004731819,0.0000936797,0.001725896,0.01130202,0.00043639,0.008548266,0.00005378875],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9753677,0.003169573,0.001261628,0.001076863,0.000273666,0.007378459,0.004251107,0.0003390704,0.006881899],"genre_scores_gemma":[0.971092,0.001943475,0.002635249,0.001947864,0.0001616961,0.006811808,0.006061217,0.00007355317,0.009273123],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005490433,"threshold_uncertainty_score":0.01836729,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1059511622138971,"score_gpt":0.4693189572583353,"score_spread":0.3633677950444382,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}